CTOs on the Move

3 Prime

www.3prime.com

 
3 Prime is a Aston, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.3prime.com
  • 2 New Rd Ste 300
    Aston, PA USA 19014
  • Phone: 610.459.3468

Executives

Name Title Contact Details

Similar Companies

Palatin Technologies

Palatin Technologies is a Cranbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Med-Metrix

Med-Metrix is a leading provider of performance management analytics, consulting, extended business office, and revenue recovery services to the healthcare industry. Our firm was founded by a veteran management team with a successful track record providing superior service and technology to Hospitals.

Therics Inc

Therics Inc is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Contrafect

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

Lumos Pharma

Lumos Pharma, based in Austin, Texas, is an early stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency.